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Interferons (IFNs) induce an antiviral state in the cell through complex and indirect mechanisms, which culminate in a
direct inhibition of viral replication and stimulation of the host adaptive responses. Viruses often counteract with elaborate
strategies to interfere with the induction as well as action of IFN effector molecules. This evolutionary battle between viruses
and IFN components is a subject of intense research aimed at understanding the immunopathogenesis of viruses and the
molecular basis of IFN signaling and action. In the case with hepatitis C virus (HCV), this may have profound implications for
the therapeutic use of recombinant IFN in treating chronic hepatitis C. Depending on the subtype of HCV, current IFN-based
treatment regimens are effective for only a small subset of chronic hepatitis C patients. Thus, one of the Holy Grails in HCV
research is to understand the mechanisms by which the virus may evade IFN antiviral surveillance and establish persistent
infection, which may eventually provide insights into new avenues for better antiviral therapy. Despite the lack of an efficient
tissue culture system and an appropriate animal model for HCV infection, several mechanisms have been proposed based
on clinical studies and in vitro experiments. This minireview focuses on the HCV NS5A nonstructural protein, which is
implicated in playing a role in HCV tolerance to IFN treatment, possibly in part through its ability to inhibit the cellular
IFN-induced PKR protein kinase. © 2001 Academic Press
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Not since the scientific community discovered the hu-
man immunodeficiency virus (HIV), has there been such
an explosion of basic and clinical research activities
directed toward a pandemic virus. A hepacivirus belong-
ing to the Flaviviridae family, hepatitis C virus (HCV) is
responsible for chronic liver disease that often leads to
liver cirrhosis, hepatic failure and hepatocellular carci-
noma (Di Bisceglie, 1998). Although hepatocytes are the
major target site of HCV infection, viral replication has
also been detected in other organs and cell types, in
particular lymphoid cells (Manns and Rambusch, 1999).
Therefore, apart from being the leading indication for
liver transplantation in the United States, chronic HCV
infection is also a major risk factor for the development
of autoimmune diseases, including mixed cryoglobuline-
mia and glomerulonephritis. There is currently no vac-
cine for HCV, which infects approximately 2.0% of the
world population, including 4.0 million Americans (Alter
et al., 1999). With up to 10,000 deaths each year in the
1 To whom correspondence and reprint requests should be ad-
ressed at Infectious Diseases Research, DC 0438, Lilly Corporate
enter, Eli Lilly and Company, Indianapolis, IN 46285. Fax: 317-276-
743. E-mail: tan_seng-lai@lilly.com.
1United States and an estimated 230,000 new HCV infec-
tions annually worldwide, chronic hepatitis C is poised to
become a serious global medical problem with consid-
erable burden on the health care system.
More than two decades ago, intense research was
focused on the potential therapeutic use of interferons
(IFNs). IFNs are a family of cytokines secreted in eukary-
otic cells early in response to various stimuli, particularly
viral infection (Vilcek and Sen, 1996; Biron, 1998). Upon
binding to their specific cell surface receptors of target
cells, IFNs trigger a cascade of intracellular reactions
that culminate in the induction of a large number of
genes whose protein products mediate the pleiotropic
multiple effects of IFN. These include induction of an
antiviral state in their target cell, immune stimulation, and
cell growth and differentiation. Because of these proper-
ties, recombinant forms of IFNs were then touted as a
panacea for a wide range of illnesses, including cancers
and viral disease (Borden and Parkinson, 1998). How-
ever, IFNs have not produced the results the public had
hoped for, although they have been used with some
success in the treatment of a number of malignancies,
including hairy cell leukemia, metastasizing renal carci-
noma, AIDS-associated Kaposi sarcomas, as well as
viral infections such as hepatitis B and human papillo-
mavirus. Perhaps the therapeutic use of IFNs has had
0042-6822/01 $35.00
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2 MINIREVIEWthe most profound impact on the treatment of chronic
hepatitis C. First approved by the Food and Drug Admin-
istration in 1991, recombinant IFN-a, alone or in combi-
nation with the synthetic guanosine analogue ribavirin,
remains the treatment of choice for chronic HCV infec-
tion today, despite the severe side effects associated
with its use in the clinic.
However, IFN-a monotherapy leads to sustained viral
clearance in only 10-15% of HCV-infected patients
(Hoofnagle, 1999). The recent introduction of ribavirin
has resulted in only moderate improvement, with 30% of
patients achieving a sustained virologic response to the
combination therapy (McHutchinson et al., 1998; Batta-
glia and Hagmeyer, 2000). Therefore, overcoming IFN
resistance remains a major challenge for effective IFN-
based therapy and future management of the HCV pan-
demic. In view of that, there is tremendous interest to
determine the molecular basis for HCV nonresponsive-
ness to IFN therapy, which may provide insights into
improved therapeutic modalities. This remains a difficult
and challenging task, as neither an efficient in vitro
culture system nor a small animal model is available for
HCV infection and propagation (Gale and Beard, 2001).
The first hint of a potential molecular mechanism for HCV
evasion of IFN response was suggested when clinical
observations showed a substantial correlation between
mutations in the viral NS5A gene from certain HCV ge-
notypes and response to IFN-a treatment in HCV-in-
fected patients.
HCV RESISTANCE TO IFN THERAPY:
THE ISDR STORY
Despite the lack of an adequate tissue culture system
for HCV infection and replication, viral proteins have
been identified and characterized by the use of in vitro
transcription/translation systems and the transfection of
recombinant clones (Reed and Rice, 2000). The HCV
genome is a 9.6-kb positive-sense single-stranded RNA
containing a 59 nontranslated region (NTR), a single open
reading frame that encodes a polyprotein of ;3000
amino acids, and a short 39 NTR (for reviews, see Bar-
tenschlager and Lohman, 2000). The 59 NTR, which is the
ost highly conserved region among HCV isolates, con-
ains an internal ribosome entry site that directs the
ranslation of the viral polyprotein. The HCV polyprotein
recursor is co- and post-translationally cleaved by viral
roteases and host cell signal peptidases, resulting in at
east three structural (core, E1, and E2) and six nonstruc-
ural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B).
arly research efforts have focused on the viral enzymes
ssential for HCV replication, including the NS3 serine
rotease/helicase and the NS5B RNA-dependent RNA
olymerase. The NS5A nonstructural protein, which has
o recognized sequence motif or known enzymatic ac-
ivity, has received little attention until 1995 when it wasirst linked to IFN responsiveness in HCV-infected pa-
ients.
HCV resistance to IFN therapy is loosely defined as
he continual presence of HCV RNA in patient serum
fter treatment (Pawlotsky, 2000). As with many RNA
iruses, HCV circulates in the host as a population of
uasispecies, most likely selected from mutations accu-
ulated in the HCV genome due to infidelity of the NS5B
NA polymerase during viral replication (Bukh et al.,
995). Different HCV isolates or genotypes display differ-
nt levels of sensitivity to IFN treatment. HCV genotypes
and 4 are particularly less sensitive to IFN therapy than
re HCV genotypes 2 and 3; the latter groups display up
o 85% response to peglyated IFN and ribavirin combi-
ation therapy. This is problematic in the United States
here HCV genotype 1 is the predominant form. Since
CV genome differences may affect the structure and
unction of viral genome and proteins, these modifica-
ions may in turn affect their interactions with numerous
ost cell functions, including those involved in the anti-
iral action of IFN in infected cells. To begin to elucidate
he mechanisms by which select HCV variants escape
he antiviral effects of IFN, Enomoto and colleagues
ompared full-length sequences of IFN-a-responsive
and -nonresponsive viruses from HCV-infected patients
(Enomoto et al., 1995, 1996). Patients who completely
responded to IFN therapy were found to carry HCV 1b
genotype isolates that contained recurring multiple mu-
tations ($4) within a discrete region of 40 amino acids in
the carboxyl half of NS5A, which corresponds to resi-
dues 2209 to 2248 of the HCV polyprotein (Fig. 1). These
observations suggest that this NS5A region, termed the
IFN sensitivity-determining region (ISDR), may play a role
in HCV resistance to IFN treatment.
However, the predictive value of ISDR in IFN therapeu-
tic outcome, especially for European and North Ameri-
can HCV isolates, has been questioned by other studies
(reviewed by Herion and Hoofnagle, 1997; Korth and
Katze, 2000). These apparently discrepant results are
often difficult to compare or interpret considering the
small numbers of patients examined in each study and
different IFN treatment regimens, as well as insufficient
data on important parameters such as time of viral ex-
posure, the host immune response, and the severity of
HCV-related disease. Furthermore, methodologic biases
in the definition and selection of sensitive and resistant
HCV isolates as well as in the generation of NS5A se-
quences may also account for the conflicting results.
Nevertheless, a recent study based on a new statistical
analysis of a database of 675 published individual ISDR
sequences strongly support the correlation of NS5A
ISDR with the IFN response (Witherell and Beineke,
2001).
Despite this controversy, the ISDR provides the first
hint of a potential molecular mechanism by which spe-
cific HCV genotypes might escape the IFN response,
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3MINIREVIEWthereby contributing to the low response rate of HCV to
IFN therapy. Enomoto et al. (1996) proposed that HCV
iruses that are resistant to IFN therapy contain multiple
utations in the ISDR, which may affect NS5A interaction
ith one or more IFN-induced antiviral effectors. In sup-
ort of this hypothesis, we have demonstrated that NS5A
s able to interact with and inhibit the IFN-induced PKR
rotein kinase, a primary mediator of the IFN-induced
ntiviral response.
HCV NS5A INHIBITION OF PKR: A NEW FOE
FOR AN OLD FRIEND
PKR is one of the few known intracellular enzymes that
re induced by IFNs and which have been well charac-
erized in terms of their antiviral properties in the cell
reviewed by Kaufman, 2000). The PKR protein kinase
an be activated by a variety of stress signals, including
he presence of viral specific double-stranded (ds) RNA
n the cell. The host presumably uses dsRNA as a critical
ignal to mobilize the innate system because dsRNA or
NA with similar secondary structures is a common
eplicative intermediate generated by a large number of
iruses. Upon activation via a dsRNA-binding induced
rotein conformational change, PKR phosphorylates the
FIG. 1. Structural and functional domains of NS5A. NS5A contain
homologous to SH3-binding motifs and a potential nuclear localization
ylation site, serine 2194, putative hyperphosphorylation sites, caspas
sensitivity-determining region (ISDR) are also indicated. The region tha
Grb2 adaptor protein or exerts trans-activating activity is indicated by
See text for further details.TP-binding eukaryotic initiation factor 2 (eIF2). The eIF2
acilitates binding of the initiator Met-tRNAi
Met to the 40S
p
iribosomal subunit during translation initiation. Phosphor-
ylation of the a subunit of eIF2 (eIF2a) on Ser51 by PKR
onverts eIF2 into a competitive inhibitor of its guanine
ucleotide exchange factor eIF2B, resulting in the inhi-
ition of general cellular protein synthesis and hence
irus replication. Viruses must therefore abrogate PKR
ction to avoid the detrimental effects associated with a
KR-mediated translational block.
Different viruses use distinct strategies to work
gainst PKR function depending on their viral replication
ycle and genome size (gene-coding capacity) (reviewed
y Gale and Katze, 1998b, 2000). Adenovirus and Ep-
tein–Barr virus counteract by encoding small RNA tran-
cripts that form an inhibitory complex with PKR, thereby
unctioning as a competitive inhibitor of dsRNA binding.
eovirus, vaccinia virus (VV), and influenza virus utilize
iral dsRNA-binding proteins, s3, E3L and NS1, respec-
tively, to sequester dsRNA activators of PKR. Some vi-
ruses employ more than one tactic to neutralize PKR.
Influenza virus also encodes a novel mechanism to re-
press PKR activity by activating the cellular P58IPK inhib-
itor, which binds to and possibly blocks PKR from dimer
formation. VV directs another viral protein, K3L, to act as
a pseudosubstrate of PKR, competing with eFI2a for
ghly conserved proline-rich region (amino acids 2322–2328) that is
l (amino acids 2328–2336). The locations of the conserved phosphor-
ated cleavage sites (}), NS4A interaction region, and the interferon
tes interaction with the IFN-induced PKR protein kinase or the cellular
bar. Amino acid numbers represent positions in the HCV polyprotein.s a hi
signa
e-medi
t mediahosphorylation. In the case of VV, mutant viruses lack-
ng K3L display an IFN-sensitive phenotype partly be-
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4 MINIREVIEWcause of the failure to inactivate PKR. A more direct
mechanism for counteracting PKR is employed by her-
pes simplex virus (HSV), which encodes the g1ICP34.5
rotein to recruit the cellular protein phosphatase 1 cat-
lytic subunit to dephosphorylate eIF2a.
The NS5A 56/58-kDa phosphoprotein is believed to be
art of the viral replicase complex, as it can be co-
mmunoprecipitated with other viral nonstructural pro-
eins (Hijikata et al., 1993). Based on heterologous ex-
ression of NS5A in cell culture and in vitro systems, we
emonstrated NS5A is capable of interacting with and
nhibiting PKR (Gale et al., 1996, 1997). The ability of
S5A to bind PKR apparently requires the ISDR as well
s adjacent 26 amino acids downstream (Gale et al.,
998a; Fig. 1). Consistent with the idea that NS5A inhibits
KR in an ISDR-dependent mechanism, the introduction
f specific mutations within the ISDR identical to those in
FN-responsive strains of HCV abolished the ability of
S5A to bind to PKR or inhibit PKR function and eIF2a
phosphorylation in a yeast system. These results sug-
gest that mutations in the ISDR can disrupt the NS5A-
PKR interaction and possibly render HCV isolates con-
taining such mutations susceptible to IFN therapy. Addi-
tional in vitro studies revealed that NS5A may function in
a fashion analogous to the cellular P58IPK inhibitor of PKR
in that it also binds to a region of PKR previously shown
to mediate kinase dimerization (Gale et al., 1998a). How-
ever, this has not yet been validated by in vivo experi-
ments and it is not known whether mutations in the ISDR
or the adjacent downstream sequence can disrupt PKR
dimer formation.
Recently PKR has been established as an apoptotic
effector capable of mediating apoptosis in response to
stress signals (Tan and Katze, 1999). We found that NS5A
could interfere with the ability of PKR to mediate the
dsRNA-dependent apoptotic pathway (Gale et al., 1999).
NIH 3T3 cell lines that constitutively expressed wild-type
NS5A, but not an ISDR deletion mutant, significantly
decreased the number of apoptotic cells in response to
dsRNA treatment, as by DNA fragmentation using the
TUNEL assay. In a separate study by Ghosh et al. (2000),
both the MTT assay and Annexin V staining were used to
demonstrate an inhibition of TNF-a-induced apoptosis by
NS5A expression in hepatoma HepG2 cells, although in
this case NS5A may function by blocking the activation of
caspase-3. Interestingly, PKR has been shown to poten-
tiate apoptosis through activation of the caspase-medi-
ated death pathway (Tan and Katze, 1999; Balachandran
et al., 2000; Gil and Esteban, 2000). Moreover, caspase 3
has been demonstrated to modulate the efficiency of
protein synthesis by cleaving eIF2a (Satoh et al., 1999).
aken together, these studies suggest NS5A may pos-
ess antiapoptotic properties, at least in part due to its
bility to neutralize PKR function(s). Inhibition of PKR and
aspase 3, or other related caspases, may therefore
nable HCV to avoid specific host apoptotic pathwaysnd thus contribute to the antiviral actions of IFN. In
ddition, since apoptosis is a common cellular response
o virus infection, it is enticing to speculate that the
ntiapoptotic properties of NS5A may play a role in the
bility of HCV to develop a persistent infection. However,
his notion is challenged when a recent study found
S5A expression in HeLa cells did not inhibit dsRNA-
nduced apoptosis, which was scored only on the basis
f cell viability assayed by trypan blue exclusion (Ezelle
t al., 2001). Whether this discrepancy is due to the
ifference in assays and/or cell lines used in these
tudies remains to be clarified.
The PKR-dependent antiapoptotic properties of NS5A
ay also contribute to the mechanism by which HCV
nfection leads to hepatocellular carcinoma. In support of
his view, constitutive expression of NS5A could induce a
ransformed phenotype in murine NIH 3T3 fibroblasts
Gale et al., 1999; Ghosh et al., 1999). Not surprisingly,
injection of these transformed cells into nude mice re-
sulted in tumor formation (Gale et al., 1999). Although
cells expressing an ISDR deletion mutant also exhibited
a growth-stimulatory phenotype, they did not induce tu-
mor formation when injected into nude mice. Thus, while
the mechanism by which NS5A transforms cells is not
fully understood, it is likely that the oncogenic properties
of NS5A are partly related to its ability to inhibit PKR.
However, it remains to be seen whether the expression
of the NS5A protein alone or in combination with an
established oncoprotein(s) is sufficient to immortalize
primary fibroblasts. Moreover, caution should be taken
when interpreting results obtained from overexpression
studies in nonphysiologically relevant systems. On this
note, there is some conflicting data in that constitutive
expression of NS5A in human osteosarcoma (U2-OS) cell
lines resulted in a cytopathic effect and severely reduced
proliferation (Polyak et al., 1999). More recently, expres-
sion of NS5A in Chang human liver cells has been shown
to result in reduced cell proliferation and colony forma-
tion efficiency (Arima et al., 2001). In this system, NS5A
appears to act by targeting the CDK1/2-cyclin complex,
leading to a delay in cell cycle progression, although the
exact mechanisms are not known.
NS5A SUPPRESSION OF IFN-INDUCED
ANTIVIRAL ACTIVITY
Despite the demonstration that NS5A inhibits PKR,
direct examination of the role of NS5A in mediating IFN
resistance is limited by the inability to propagate HCV in
cell culture system. We and others have thus examined
whether expression of NS5A could at least reduce the
IFN-induced antiviral effects in cells and therefore allow
viral protein synthesis and replication in infected cells. In
the absence of NS5A expression, IFN treatment signifi-
cantly inhibited the protein synthesis of normally IFN-
sensitive viruses, including vesicular stomatitis virus
5MINIREVIEW(VSV) (Gale et al., 1999) and VV (He et al., 2001) in
infected HeLa cells. In contrast, viral protein synthesis
was partially restored in HeLa cells stably expressing
NS5A or cells infected with recombinant VV expressing
NS5A. Importantly, these results correlated with the
phosphorylation levels of PKR and eIF2a in the infected
cells. Similarly, other investigators have demonstrated
that NS5A expression alone partially inhibited IFN anti-
viral action in other mammalian cell lines, including US-
OS, HepG2 cells, and L929 murine fibroblasts, allowing
replication of encephalomyocarditis virus (EMCV) and
VSV during IFN challenge (Paterson et al., 1999; Polyak et
al., 1999; Song et al., 1999; Aizaki et al., 2000).
While the above studies cumulatively suggest that
NS5A expression alone confers partial resistance to the
antiviral effects of IFN against IFN-sensitive viruses, the
involvement of the ISDR is less clear. Expression of
NS5A containing substitutions in the ISDR resembling
those from an IFN-sensitive HCV 1b genotype strain is
unable to rescue VSV protein synthesis in HeLa cells
(Gale et al., 1999) during IFN challenge. Furthermore,
NS5A from a HCV 1b genotype strain is more efficient in
suppressing the IFN antiviral affects than that from a
HCV 1a genotype strain in HepG2 cells (Polyak et al.,
1999). Song et al. (1999) also showed that expression of
the NS5A protein derived from an IFN resistant, but not
an IFN sensitive, HCV 1b subtype strain can block the
IFN action against VSV in L929 cells, although the effect
against Japanese encephalitis virus is marginal. This
inhibition is significantly weaker when a short stretch of
the IFN-resistant NS5A, including the ISDR, is replaced
with the corresponding fragment from the IFN sensitive
HCV strain.
On the contrary, human amnion-derived FL cell lines
expressing an NS5A containing a mutated ISDR se-
quence corresponding to that of an IFN-resistant HCV
isolate are still able to rescue EMCV replication when
challenged with IFN (Aizaki et al., 2000). In HepG2 cells,
expression of an NS5A form devoid of the ISDR also
retains the ability to suppress the IFN-induced antiviral
activity against EMCV (Polyak et al., 1999). Another study
actually found NS5A clones derived from an IFN respon-
sive patient were much more potent inhibitors of IFN
antiviral effects than those derived from a nonresponder
when expressed in human fibroblast cells (Paterson et
al., 1999). When Francois et al. (2000) analyzed the IFN
response of a human cell line UHCV-11 engineered to
inducibly express the entire HCV genotype 1a polypro-
tein, they found that expression of HCV proteins could
also support EMCV replication better than vector control
cells during IFN challenge. The resistance of UHCV-11
cells to IFN appeared independent of inhibition of PKR in
that there was no detectable colocalization of PKR and
HCV proteins or change in either PKR activity or eIF2a
phosphorylation in these cell lines. However, this study
did not determine which HCV protein(s) is responsiblefor conferring the IFN resistance to EMCV. Taken to-
gether, these studies suggest that NS5A may also coun-
teract the antiviral effects of IFN via other mechanisms
independent of the ISDR or its interaction with PKR.
A significant advancement in HCV research came with
the development of a subgenomic biscistronic HCV rep-
licon DNA construct containing a selectable marker
gene (neomycin phosphotransferase) and genes encod-
ing the viral nonstructural proteins (Lohman et al., 1999).
In this system, the HCV IRES directs the translation of the
neo gene, whereas the expression of the HCV nonstruc-
tural genes is mediated by the IRES of EMCV. Transfec-
tion of RNA transcribed from this construct into the hep-
atoma cell line Huh-7 cells resulted in selectable auton-
omous replicating HCV subgenomic RNAs, providing for
the first time a tool to investigate HCV replication in cell
culture and the molecular interactions between HCV and
its host. However, despite the relatively high replication
levels of the HCV subgenomic RNAs within selected
cells, the number of G418-resistant colonies is too low for
robust analysis. More recently, several investigators
identified and characterized a number of adaptive muta-
tions that enhanced the initiation of the replication of the
HCV replicon, as scored by increased efficiency of col-
ony formation by several orders of magnitude (Blight et
al., 2000; Lohmann et al., 2001; Pietschmann et al., 2001).
Intriguingly, in one study, a majority of these adaptive
mutations were localized within NS5A, including a dele-
tion of the entire ISDR (Blight et al., 2000). In addition, the
HCV replicons were highly sensitive to IFN-a treatment
in that replication of the adapted HCV subgenomic RNA
could readily be blocked by treatment of cells with IFN-a
(Blight et al., 2000; Frese et al., 2001). The absence of the
ISDR did not appear to significantly affect the sensitivity
of the replicon to the IFN treatment, suggesting that the
ISDR is nonessential for HCV replication and IFN resis-
tance (Blight et al., 2000). However, deletion of the ISDR
rendered the lowest transduction efficiency among all of
the culture-adaptive mutations identified. Thus, the ISDR
may contribute to the overall efficiency of HCV RNA
replication, perhaps through the regulation of PKR. How-
ever, the level and activity of endogenous IFN-inducible
genes, including PKR, were not examined in this study.
Very recent work suggests that specific dsRNA struc-
tures within the HCV replicon RNA are sufficient to acti-
vate PKR in vivo, and that efficient HCV RNA replication
may correspond with a block in PKR-dependent signal-
ing pathways of the host cell (M. J. Gale, Jr., personal
communication).
It is still not clear how IFN-a inhibits HCV subgenomic
replication in the replicon: by preventing the accumula-
tion of RNA at the transcription or degradation step, or by
blocking synthesis or function of viral proteins. At any
rate, results obtained from these studies must be inter-
preted with caution, as the replicon is still by no means
a viral infection system; there is no virion propagation
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6 MINIREVIEWand assembly due to the lack of structural proteins.
Furthermore, there are recent reports suggesting that
Huh-7 cells may be inherently defective in IFN response
mechanism (Keskinen et al., 1999; Melen et al., 2000).
he definition of replicon sensitivity to IFN is not clear;
here is no systematic analysis of the quantitative effect
f different doses of IFN-a on HCV subgenomic RNA
replication over a time course to determine the kinetics
of the IFN action. Moreover, the possibility that the ob-
served inhibition of HCV subgenomic RNA replication
after IFN-a treatment is due to a block in EMCV IRES
activity, which could result in a reduction of HCV protein
synthesis and consequently RNA replication, has not
been excluded.
HCV May Encode a Two-Pronged Approach to Inhibit
PKR
The E2 glycoprotein of HCV has also recently been
shown to interact with and inhibit PKR (Taylor et al.,
1999). This hypothesis originally stemmed from the ob-
servation that the E2 protein contains a 12-amino-acid
sequence that shares high homology with several puta-
tive autophosphorylation sites within the N-terminal reg-
ulatory domain of PKR, as well as its natural substrate,
eIF2a. This region termed PePHD (for PKR-eIF2a phos-
horylation homology domain) was subsequently shown
o be required for E2 inhibition of PKR in yeast. Although
he exact mechanism by which E2 inhibits PKR is not
lear, a recent follow-up study suggests E2 is unlikely to
ct as pseudosubstrate to compete with the PKR auto-
hosphorylation sites (Taylor et al., 2001). Interestingly,
E2 sequences from HCV gentoypes 1a and 1b, which
share higher homology to PKR than genotypes 2a, 2b, or
3a, are generally more resistant to IFN therapy than
genotypes 2 and 3, suggesting that E2 inhibition of PKR
may also contribute to HCV resistance to IFN treatment.
However, an increasing number of clinical studies dem-
onstrate that the PePHD is a highly conserved region
with no significant mutations accumulated during IFN
therapy (Berg et al., 2000; Chayama et al., 2000; Co-
hrane et al., 2000; Gerotto et al., 2000; Polyak et al.,
000; Sarrazin et al., 2000). Furthermore, the ability of E2
o confer IFN resistance to IFN-sensitive viruses has not
een demonstrated. Thus, the role of E2 in mediating
CV resistance to IFN action remains to be established.
elevance of NS5A Trans-activating Properties
There is also evidence that the carboxyl-terminal do-
ain of NS5A, including the ISDR, contains nonspecific
rans-activating activity in both yeast and mammalian
ells when fused to the DNA-binding domain of GAL4,
uggesting that NS5A might function as a viral trans-
ctivator (Tanimoto et al., 1997; Kato et al., 1997). Inter-
stingly, the introduction of mutations derived from HCV
solates from IFN-responsive patients into the ISDR cannhance the trans-activating activity of NS5A in the arti-
icial GAL4 system (Fukuma et al., 1998). Despite the
resence of a putative nuclear localization signal (NLS)
n its C-terminal region (Ide et al., 1996) (Fig. 1), NS5A is
redominantly localized in the cytoplasm and/or nuclear
eriplasmic membrane. Furthermore, it has been re-
orted that NS5A may be cleaved by a caspase-like
rotease(s) in mammalian cells (Song et al., 2000), pos-
ibly in an apoptotic-dependent manner (Satoh et al.,
000). The cleaved NS5A forms, which lack potential
LS-masking sequence in the N-terminal region, are
ocalized in the nucleus and display transcriptional ac-
ivity when co-expressed with the a-catalytic subunit of
rotein kinase A (PKA), which has previously been
hown to phosphorylate NS5A in vitro (Ide et al., 1997).
everal recent studies found that NS5A is capable of
nteracting with cellular transcriptional factors, including
novel cellular transcription factor SRCAP (Ghosh et al.,
000) and P53 (Majumder et al., 2001), as well as a
uclear import machinery component named karyo-
herin b3 protein (Chung et al., 2000). However, the
biological consequences of these interactions are not
known.
A recent study found elevated levels of the pro-inflam-
matory chemokine, interleukin-8 (IL-8), in IFN nonrespon-
sive patients as well as in NS5A-expressing HeLa cells
(Polyak et al., 2001). Interestingly, expression of N-termi-
nal truncated forms of NS5A stimulates the IL-8 promoter
to levels higher than the full-length NS5A protein in HeLa
cells, as determined by transcriptional activation of a
luciferase gene driven by IL-8 specific promoter. This
stimulation also correlates with increased nuclear local-
ization of the truncated NS5A proteins. These results
suggest NS5A may be capable of inducing the transcrip-
tion of IL-8, which was previously shown to inhibit the
antiviral actions of IFN in vitro (Khabar et al., 1997),
providing an additional mechanism for IFN resistance in
chronic hepatitis C. However, the clinical correlation be-
tween NS5A trans-activating activity, IL-8 levels, and IFN
sensitivity has not been clearly established. Furthermore,
the functional significance of the truncated form of NS5A
is not known.
INTERCEPTION OF THE IFN SIGNALING BY HCV
PKR inhibition by NS5A or E2 is likely not the only
mechanism responsible for HCV evasion of host IFN
response. Viruses also disrupt the ability of cells to
respond to IFN, either through the use of decoy recep-
tors, inhibitors of signaling components or repressors of
gene transcription (reviewed in Cebulla et al., 1999; Al-
cami and Koszinowski, 2000). The blockade of IFN sig-
naling pathways is an efficient strategy because it would
have a pleiotropic effect on the antiviral activities of IFN
and thus would be economical for viruses with limited
gene-coding capacity.
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7MINIREVIEWViral Strategies against IFN Signaling: More Than
Meets the Eye
The binding of IFNs to species-specific cell surface
receptors elicits multiple signal transduction pathways,
which lead to the induction of gene expression (Darnell
1997, 1998; Stark et al., 1998). The IFN-Stimulated Gene
Factor 3 (ISGF3) is responsible for the induction by bind-
ing to IFN-stimulated response elements (ISREs) found
in numerous IFN-induced genes. Active ISGF3 is com-
posed of three functional subunits. Two of these proteins
are named Signal Transducer and Activators of Tran-
scription (STAT) 1 and 2, which reside in the cytoplasm of
unstimulated cells. STAT1/2 proteins are tyrosine phos-
phorylated by JAK1 and Tyk2 of the Janus kinases (JAK)
family. The Tyk2 molecule binds to the intracytoplasmic
domain of one of the two cloned IFN-a receptor subunits,
IFNAR1, whereas JAK1 is constitutively associated with
the second subunit IFNAR2. IFN-a binding likely causes
he oligomerization of these receptors, which leads to
he autophosphorylation and activation of JAK1 and Tyk2.
AK1 and Tyk2 in turn phosphorylate the IFN receptors
n specific tyrosine residues, which function as docking
ites for the Src homology (SH) 2 domain of STAT1/2
roteins. Recruited STAT1/2 proteins are subsequently
hosphorylated by the JAK kinases on tyrosine residues,
eterodimerize and translocate to the nucleus where
hey bind p48, which is in direct contact with the ISRE,
hereby forming the ISGF3 active complex. In addition,
he IFN regulatory factor (IRF) family of transcription
actors also plays a critical role in regulating IFN and
FN-induced gene expression (reviewed by Taniguchi et
l., 1997). Activation of different members of STAT and
RF family and the formation of different homo- and het-
rodimers are believed to provide specific biological
esponses to different cytokines or growth factors.
Viruses have evolved different mechanisms to interdict
he IFN signaling. Some viruses secrete soluble IFN
eceptor-like polypeptides that can bind to IFNs to inhibit
heir biological activities. VV encodes a soluble viral
omolog of IFN-a/b receptor (IFN-a/bR), termed B18R,
which binds to IFN-a/b (Colamonici et al., 1995). Other
viruses perturb the signaling components of the JAK-
STAT pathway to subvert IFN action. For example, the
viral large T antigen of murine polyoma virus directly
binds to JAK1 resulting in the inhibition of its function
(Weihua et al., 1998). Human cytomegalovirus (HCMV)
apparently uses a different strategy that involves the
proteolysis of JAK1 (Miller et al., 1998). Adenoviruses
appear to directly interfere with the transcriptional re-
sponse by using the viral E1A protein (Leonard and Sen
1996). Depending on the cell types, E1A has been shown
to downregulate the levels of p48 and STAT1 (Leonard
and Sen, 1997), or disrupt the interaction of STAT proteins
with transcriptional co-activator CBP/p300 in the nucleus
(Bhattacharya et al., 1996).Human herpesvirus 8 uses a yet another mechanism
to disrupt the IFN responsive transcription apparatus.
This virus codes for a viral homolog of the IRF family
proteins, which presumably forms inactive heterodimers
with other members of the family (Zimring et al., 1998).
Human papilloma virus (HPV), which is also resistant to
IFN-a treatment, encodes two proteins to interfere with
IFN signaling: E6 binds to and inhibits Tyk2 activity (Li et
al., 1999), while E7 binds p48 and blocks its nuclear
translocation (Barnard and McMillan 1999). The terminal
protein of HBV has been shown to interrupt both Type I
and II IFN signaling by disrupting ISGF3 formation but
the exact mechanism is not known (Foster et al., 1991).
Sendai virus (SeV) may use several strategies, including
a partial inhibition of Tyk2 activation (Komatsu et al.,
2000) and suppression of STAT1 levels (Garcin et al.,
2000). The latter effects appear to require the viral C
proteins to interact with unknown cellular components.
Is HCV an Enemy of the STAT?
Could HCV also encode a mechanism to disarm the
JAK-STAT pathway? Heim and colleagues (1999) ad-
dressed this question by generating stably transfected
human US-OS cells expressing full-length HCV genome.
They found a complete inhibition of IFN-a-induced acti-
ation of ISGF3 in the HCV-expressing cells, whereas the
ontrol cells exhibited the expected activation of ISGF3,
s judged by ISGF3 binding to the ISRE by gel shift
ssays. STAT1/3 tyrosine phosphorylation was not im-
aired in these cells as revealed by immunoblot analysis
sing phospho-specific antibodies to the activated forms
f STAT1/3. Furthermore, ISGF3 showed normal nuclear
ransportation and tyrosine phosphorylation in the HCV-
xpressing cells. Although reduced expression of STAT1
nd p48 was detected in the HCV-expressing cells, it is
ot clear whether the decrease in protein expression
as the cause or result of the observed inhibition of IFN
ignaling. It should also be pointed out that serine phos-
horylation of STAT1/3 has been reported to modulate
he transcriptional activity of STAT1/3 (see discussion
elow); future studies should examine whether this step
s affected by HCV. Thus, the exact mechanisms by
hich HCV proteins inhibit IFN signaling remain to be
etermined. Nevertheless, these results are interesting
n light of previous findings that STAT1 knockout mice
isplay liver necrosis, syncytial cell formation and an
nflammatory response in their liver, which is reminiscent
f viral hepatitis (Durbin et al., 1996). The possibility that
HCV may interfere with the JAK-STAT pathway should be
followed up in future studies, including the determination
of the HCV protein(s) responsible for such action. In
regard to the role of NS5A, HeLa cells that express NS5A
do not appear to interfere with STAT1 tyrosine phosphor-
ylation or ISGF3 DNA binding activity (Polyak et al., 2001).
Recently, we found that HCV may utilize the viral NS5A
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8 MINIREVIEWprotein to perturb host intracellular signaling pathways
through its ability to interact with the adaptor protein
Grb2 (Tan et al., 1999). Using in vitro and in vivo binding
assays, we found that the NS5A protein of hepatitis C
virus (HCV) physically interacted with the cellular growth
factor receptor-bound protein 2, Grb2. The NS5A-Grb2
interaction occurred in a SH3/ligand-dependent manner;
the ligand was mapped to a highly conserved proline-
rich sequence within the C-terminal end of NS5A (Fig. 1).
Grb2 is a SH3 domain-containing adaptor protein that
mediates growth factor-induced signaling by coupling
the membrane receptor tyrosine kinases (RTKs) to the
Ras-MAPK (mitogen-activated protein kinase) pathway
(Fig. 2). Expression of NS5A can inhibit epidermal growth
factor (EGF)-induced phosphorylation of the MAP ki-
nases, extracellular-regulated kinase 1 and 2 (ERK1/2), in
HeLa cells. Furthermore, interaction with Grb2 is neces-
sary for NS5A to inhibit activation of ERK1/2 by EGF in
HeLa cells (He et al., in preparation). Together, these
FIG. 2. Potential HCV strategies against IFN response. Cross-talk bet
Ras-Raf-ERK MAP kinase pathway by nucleating the formation of signa
ylation of STAT1 at serine 727 may be required for maximal transcription
STAT1 and STAT2; GF, growth factor; GFR, growth factor receptor; IF
element; ISRE, IFN-stimulated response element; ISGF3, IFN-stimulated
functions include but are not limited to PKR, MxA, and 29-59 oligoad
postulated target sites for HCV antagonism of IFN response, including
downregulation of ISGF3. See text for further details.studies suggest that NS5A is a viral inhibitor of mitogenic
signaling, at least in part because of its ability to interact
e
mwith Grb2. It should be noted, however, that signaling
responses vary depending on the cell type and the na-
ture, strength and duration of the signal. It is therefore
important to corroborate these results, as well as the
effects of other growth factors and cytokines, particularly
those implicated in liver proliferation and apoptosis,
such hepatic growth factor, TNF-a and IL-6, in liver cells.
t is also not clear how NS5A achieves specificity in
ecognizing Grb2 upon mitogenic stimulation. Because
S5A and Grb2 interaction is inducible by EGF treatment
Tan et al., 1999), NS5A is probably transiently associated
ith Grb2 in the cytoplasm. Interestingly, Grb2 binds to a
roline-rich sequence of NS5A immediate to the putative
uclear localization signal (Fig. 1), which could block
S5A translocation to the nucleus during mitogenic stim-
lation.
Because ERK1/2 and other mitogen-activated protein
inases (MAPKs) have been implicated in the JAK-STAT
athway, NS5A inhibition of Grb2 may also affect the
he JAK-STAT and ERK signaling pathways is shown. Grb2 mediates the
uction complexes at the plasma membrane. ERK-mediated phosphor-
ity of the ISGF3 complex. JAK represents JAK1 and TYK2; STAT includes
FN-a receptor; dsRNA, double-stranded RNA; SRE, serum response
actor complex 3; ISGs, IFN-stimulated genes. ISGs with known antiviral
synthetase (2-5 OAS) (Vilcek and Sen, 1996). Block arrows indicate
- and E2-mediated inhibition of PKR, NS5A interaction with Grb2, andween t
l transd
al activ
N-aR, I
gene f
enylatexpression of IFN-stimulated genes (reviewed by Lea-
an et al., 1996, Winston and Hunter, 1996). A recent
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9MINIREVIEWstudy showed that full transcriptional activation of ISGF3
requires the p38 MAPK pathway (Goh et al., 1999; Wil-
liams, 1999). p38 was activated by Type I IFNs and its
function was essential for IFNa-induced ISRE-dependent
gene transcription but not for the DNA-binding activity of
the ISGF3 complex. Interestingly, PKR has been impli-
cated upstream of the p38 signaling pathway (Goh et al.,
2000; Iordanov et al., 2000; Williams, 1999), suggesting
yet another mechanism by which NS5A inhibition of PKR
could result in suppression of IFN action. Several recent
papers also suggest a “cross-talk” between the JAK-STAT
pathway and the ERK pathway (Fig. 2). It has been shown
that ERK-mediated serine phosphorylation of STAT1 and
STAT3 is required for the optimal activation of these STAT
proteins (David et al., 1995, 1996; Wen and Darnell, 1995;
Zhang et al., 1995), although this may be cell type-spe-
cific (Chung et al., 1997; Jain et al., 1998). Thus, NS5A
perturbation of both the ERK and the p38 MAPK path-
ways, through its ability to bind Grb2 and/or PKR, may
decrease the serine phosphorylation of STAT1/3, result-
ing in the disruption of IFN-induced gene expression,
thereby providing an alternative mechanism for HCV
resistance to IFN. In this regard, it is interesting to note
that SeV and simian virus 5, both of which disrupt IFN
signaling, have been shown to reduce the serine phos-
phorylation of STAT1a (Young et al., 2000).
CONCLUDING REMARKS AND
FUTURE DIRECTIONS
Many hypotheses regarding HCV pathogenesis and
the host IFN response to HCV infection are derived
mainly from clinical observations and from expression
analyses of selected genes in nonhuman cells or non-
hepatocyte cells. Thus the vast amounts of data gener-
ated must be validated in normal human hepatocyte
cells, relevant animal models, as well as in the context of
a natural HCV infection. Exciting prospects are antici-
pated with the recent success in the development of
infectious HCV molecular clones in small animal models
(Gale and Beard, 2001), and the advent of large-scale
gene expression profiling technologies (Manger and Rel-
man, 2000). In an interesting study using suppression-
subtractive hybridization, expression of several IFN-a/b-
nduced genes in the liver of chronic hepatitis C patients
as found to be significantly enhanced, indicating that
CV may be an inducer of IFN-a/b-inducible genes
(Patzwahl et al., 2001). These genes, which include IP-10,
xA, IFI-56K, and p44, have been previously implicated
n the cellular antiviral response. Whether HCV also
ncodes mechanisms to counteract these gene products
emains to be determined. However, since common se-
uences have been removed from the subtracted library,
his analysis is not an accurate reflection of the infected
iver gene expression profile. The use of differential dis-
lay analysis or DNA microarray technology should pro-ide a more comprehensive survey of cellular gene ex-
ression in the presence or absence of HCV infection.
ith respect to IFN response, these methods have been
sed to identify IFN-induced genes whose expression is
ltered during infection by HCMV (Zhu et al., 1997), HPV
Chang and Laimins, 2000), and HSV (Mossman et al.,
001).
NS5A is likely to play an important role in virus–host
nteraction and the regulation of viral replication, and the
iterature in general supports the role of NS5A in the
uppression of IFN-induced antiviral activity. As with
ther viruses, HCV likely employs several mechanisms
o counteract the IFN response (Fig. 2). NS5A is phos-
horylated on multiple serine residues and exists in two
pecies: a basal phosphorylated form of 56 kDa and a
yperphosphorylated form of 58 kDa (Kaneko et al.,
994). Although several cellular protein kinases have
een shown to phosphorylate NS5A in vitro (Idle et al.,
997; Kim et al., 1999), the physiological relevance of
hese results remain to be shown. In this regard, we have
ecently found that serine 2194 is a highly conserved
hosphorylation site of NS5A (Katze et al., 2000). PKR
oes not appear to phosphorylate NS5A (Reed and Rice,
999) and mutation of serine 2194 does not effect the
bility of NS5A to bind PKR in vitro (Katze et al., 2000).
nterestingly, adapted HCV replicons that have acquired
igher replication efficiency contain mutations in several
utative hyperphosphorylation sites of NS5A (Fig. 1),
uggesting that hyperphosphorylation of NS5A is not
ssential for viral replication (Blight et al., 2000). The
yperphosphorylated NS5A is apparently generated
lower and less stable compared to the basal phosphor-
lated NS5A and other nonstructural proteins, suggest-
ng that the two NS5A variants may serve distinct func-
ions during different stages of HCV replication
Pietschmann et al., 2001). Clearly, the identification of
he cellular protein kinase(s) that is responsible for dif-
erential phosphorylation of NS5A will provide further
nsights into NS5A function and regulation.
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